A Phase 1, Randomized, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Emraclidine Following Multiple Oral Doses in Healthy Elderly Participants (Part A) and to Evaluate the Safety and Tolerability of Emraclidine in Participants With Dementia Due to Alzheimer's Disease (Part B)
Latest Information Update: 12 May 2025
At a glance
- Drugs Emraclidine (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cerevel Therapeutics
Most Recent Events
- 02 May 2025 Status changed from active, no longer recruiting to completed.
- 26 Mar 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Apr 2025.
- 26 Mar 2025 Status changed from recruiting to active, no longer recruiting.